Hey guys, so in the pathway for the basal ganglia, First Aid states that dopamine activate D1 receptors to stimulate movement and it activates D2 receptors to inhibit movement. However, some of the drugs that are used to treat Parkinsons (ropinirole) are D2 receptor agonists, so wouldn't that worsen Parkinsons disease symptoms since you are stimulating a receptor that decreases movement in a patient who already suffers from bradykinesia?
-
CycleTrack and SDN are teaming up to make medical school admissions more transparent and accessible! Read the announcement to learn how we’re supporting the future of CycleTrack’s free application-tracking tools .
USMLE/COMLEX Parkinsons disease Question
Started by ChaoWow
Get help with your application
Use all the free resources available to you from SDN: articles, guides, expert advising, forums discussions, and school research.